Becton, Dickinson and Company (BDX) to Release Earnings on Thursday

Key Points

• On Thursday, May 7, Becton, Dickinson will report Q2 2026 results before the open; analysts expect $2.77 EPS and $4.666B revenue, and the company has set FY2026 guidance at $12.35–$12.65 EPS.
• In the prior quarter BD beat EPS but materially missed revenue, prompting analyst price-target cuts and split sentiment; shares are trading below the 50‑ and 200‑day moving averages, adding technical pressure.
• The board approved a $10 million share buyback authorization and declared a quarterly dividend of $1.05 (2.9% yield), signaling ongoing capital returns to shareholders.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) is expected to release its Q2 2026 results before the market opens on Thursday, May 7th. Analysts expect Becton, Dickinson and Company to post earnings of $2.77 per share and revenue of $4.6661 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Interested persons can find conference call details on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $4.49 billion for the quarter, compared to analysts' expectations of $5.15 billion. During the same period last year, the firm earned $3.43 EPS. The company's quarterly revenue was up 1.6% on a year-over-year basis. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $145.27 on Thursday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $41.36 billion, a PE ratio of 23.70, a price-to-earnings-growth ratio of 10.68 and a beta of 0.29. The stock's 50-day moving average price is $161.35 and its 200-day moving average price is $182.22.

Becton, Dickinson and Company announced that its board has approved a share buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 68.52%.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD launched the BD® CentroVena One™ all‑in‑one central venous catheter insertion system — a first‑of‑its‑kind commercial product that can drive adoption in acute care and supports BD’s interventional/vascular access growth story. BD CentroVena One launch
• Positive Sentiment: The Board declared a quarterly dividend of $1.05 (payable June 30), maintaining yield and signaling continued cash return to shareholders. That supports income-minded holders and underpins the stock’s defensive appeal. Dividend announcement
• Neutral Sentiment: BD’s latest quarter showed an EPS beat but a material revenue miss; FY‑2026 EPS guidance (12.35–12.65) is roughly in line with consensus — mixed fundamentals that leave valuation and execution the focus. Quarterly results & guidance
• Neutral Sentiment: Market commentary is debating whether recent share weakness is a buying opportunity; some analysts maintain buy ratings while several have lowered targets, so sentiment is split. Is It Time To Reconsider BDX?
• Negative Sentiment: Revenue shortfall and subsequent analyst target cuts/“hold” adjustments have likely triggered selling — these are the primary near‑term drivers of share weakness. Analyst coverage & price targets
• Negative Sentiment: Technical pressure: shares are trading below the 50‑ and 200‑day moving averages, which can accelerate outflows from trend‑sensitive funds. Stock technicals
• Negative Sentiment: A small insider sale (EVP sold 74 shares under a Rule 10b5‑1 plan) was disclosed; the transaction is routine and pre‑arranged but can be cited by short‑term traders as a negative signal. Insider sale disclosure

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 1,102 shares of company stock valued at $198,909. Insiders own 0.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Zions Bancorporation National Association UT lifted its stake in Becton, Dickinson and Company by 18.3% in the 4th quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier's stock worth $187,000 after purchasing an additional 149 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $124,000. Acumen Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $120,000. Finally, Caden Capital Partners LP purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $101,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BDX. Barclays began coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an "overweight" rating and a $202.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating on the stock in a report on Tuesday, February 10th. Piper Sandler lowered their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Wells Fargo & Company lowered their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 10th. Finally, Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a report on Tuesday, February 10th. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $189.08.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.